Annovis_Corp_Image.png
Annovis Bio to Present at the 2020 BIO Investor Forum
October 12, 2020 16:05 ET | Annovis Bio Inc.
BERWYN, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease
September 29, 2020 06:45 ET | Annovis Bio Inc.
Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association Study adds further validation that Annovis’ lead compound is the only drug to improve axonal...
Annovis_Corp_Image.png
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
September 03, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial
September 01, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases
August 20, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio CEO Appears on Executive Leaders Radio Program
July 23, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
July 20, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
July 07, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
June 16, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
June 09, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., June 09, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...